- Home
- ATR vs EXAS Comparison
ATR vs EXAS Comparison
Compare ATR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATR
- EXAS
- Stock Information
- Founded
- ATR 1992
- EXAS 1995
- Country
- ATR United States
- EXAS United States
- Employees
- ATR N/A
- EXAS N/A
- Industry
- ATR Plastic Products
- EXAS Medical Specialities
- Sector
- ATR Industrials
- EXAS Health Care
- Exchange
- ATR Nasdaq
- EXAS Nasdaq
- Market Cap
- ATR 9.3B
- EXAS 11.0B
- IPO Year
- ATR 1993
- EXAS N/A
- Fundamental
- Price
- ATR $116.25
- EXAS $65.83
- Analyst Decision
- ATR Buy
- EXAS Strong Buy
- Analyst Count
- ATR 4
- EXAS 21
- Target Price
- ATR $167.50
- EXAS $71.86
- AVG Volume (30 Days)
- ATR 688.4K
- EXAS 2.9M
- Earning Date
- ATR 10-30-2025
- EXAS 11-03-2025
- Dividend Yield
- ATR 1.65%
- EXAS N/A
- EPS Growth
- ATR 24.99
- EXAS N/A
- EPS
- ATR 6.23
- EXAS N/A
- Revenue
- ATR $3,662,533,000.00
- EXAS $3,082,033,000.00
- Revenue This Year
- ATR $4.30
- EXAS $16.68
- Revenue Next Year
- ATR $3.85
- EXAS $12.36
- P/E Ratio
- ATR $18.66
- EXAS N/A
- Revenue Growth
- ATR 2.50
- EXAS 14.47
- 52 Week Low
- ATR $103.23
- EXAS $38.81
- 52 Week High
- ATR $178.03
- EXAS $72.81
- Technical
- Relative Strength Index (RSI)
- ATR 25.93
- EXAS 61.04
- Support Level
- ATR $103.23
- EXAS $62.39
- Resistance Level
- ATR $116.96
- EXAS $72.81
- Average True Range (ATR)
- ATR 3.82
- EXAS 2.11
- MACD
- ATR -1.00
- EXAS -0.01
- Stochastic Oscillator
- ATR 44.95
- EXAS 30.90
About ATR AptarGroup Inc.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.